Acceleron Pharma Inc XLRN shares have gained about 39 percent since June 28 in reaction to positive Phase 3 study results for its luspatercept in low-to intermediate-risk myelodysplastic syndromes. The candidate also posted positive results in a late-stage trial that evaluated it for transfusion-dependent beta thalassemia. Source